Marinus Pharmaceuticals

Bayer Pharmaceuticals Corporation

Bayer Healthcare LLC

Yale University

Insignis Therapeutics, Inc.

Other

Mingbao Zhang

Kenneth Shaw

Lei Zhu

Derek B Lowe

Chengzhi Zhang

Andreas Stolle

Xin Ma

William H Bullock

Yamin Wang

Ming Wang

Ingo Andreas Mugge

Philip L Wickens

Manami Tsutsumi

Philip D G Coish

Hai-Jun Zhang

James N Livingston

Roger Astbury Smith

Ann-Marie Campbell

Gan Wang

Stephen J O'Connor

Ning Miao Su

Philip Coish

Miao Dai

Susan Jenkins

Raymond C Glowaky

David Czekai

Amy F T Arnsten

Derek Lowe

Philip D Coish

Ingo A Mugge

Kenneth R Shaw

This disclosure provides orally disintegrating dipivefrin tablet (ODT) formulations, including ODT formulations containing L-dipivefrin HCl. The ODT formulations of the disclosure include 10 to 70% binder (wt %), 5 to 50% matrix former (wt %), and 1 to 20% taste masking agent (wt %). The ODT formulations of the disclosure rapidly provide epinephrine to a patient when administered. The disclosure also provides a method of treating a patient who has a condition responsive to epinephrine such as a cardiac event, asthma, croup, cancer, a microbial infection, Addison's disease, or an allergic reaction, particularly anaphylaxis by administering an orally disintegrating dipivefrin tablet formulations to the patient.

Dipivefrin orally disintegrating tablet formulations

The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering dipivefrin or a dipivefrin salt to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering dipivefrin or a dipivefrin salt to a subject in need of in vivo delivery of systemic epinephrine. The disease can be a respiratory disorder, anaphylaxis, cancer, or a microbial infection. The disclosure also includes dipivefrin or dipivefrin HCl orally dissolving tablets.

Methods of using dipivefrin

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

Method of treatment using nanoparticulate ganaxolone formulations

The disclosure provides an injectable neurosteroid nanoparticle formulation comprising nanoparticles having a D50 of less than 2000 nm the nanoparticles comprising a neurosteroid of Formula I, where the variables R-Rand X are defined herein and at least one surface stabilizer. The surface stabilizer can be a polymeric surface stabilizer such as hydroxyethyl starch, dextran, or povidone. The injectable neurosteroid nanoparticle formulation can be an intravenous formulation. The disclosure also provides a lyophilized powder of the injectable neurosteroid nanoparticle formulation that can be reconstituted in an aqueous solution prior to administration. The disclosure provides injectable neurosteroid nanoparticle formulations and dry powders of such formulations that have been sterilized by ebeam irradiation. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable neurosteroid nanoparticle formulation. The disclosure also provides combination methods in which the injectable neurosteroid nanoparticle formulation is a first active agent that is administered in combination with at least one additional active agent.

Injectable neurosteroid formulations containing nanoparticles

Solid ganaxolone compositions and methods for the making and use thereof

Liquid ganaxolone formulations and methods for the making and use thereof

Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof.

Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof

Solid ganaxolone formulations and methods for the making and use thereof

This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation

Pseudobase benzo[c]phenanthridines and the pharmaceutically acceptable salts thereof of Formula I are provided herein. The variables R, R, R, R, and Rare defined herein. Certain pseudobase benzo[c]phenanthridines provided herein act as prodrugs, targeting the parent benzo[c]phenanthridinium alkaloid to hydrophilic or hydrophobic regions in the body. Pharmaceutical compositions comprising a pseudobase benzo[c]phenanthridine and a carrier, excipient, or diluent are provided herein. Methods of treating or preventing microbial, fungal and or viral infections and methods of treating diseases and disorders responsive to protein kinase C modulation, topoisomerase I, and/or topoisomerase II modulation are also provided.

Pseudobase benzo[c]phenanthridines with improved efficacy, stability and safety

Growing community of inventors

Stamford, CT, United States of America

Mingbao Zhang